Adenomyosis Linked to Higher Hysterectomy Risk After Embolization
A large U.S. claims study finds similar short-term safety for uterine artery embolization with or without coexisting adenomyosis, but more later hysterectomies.
Updated on Nov. 9, 2026 in Stroke

Live Poll
Would you trust a minimally invasive procedure to treat fibroids instead of surgery?
Image-guided uterine artery embolization showed similar 30-day outcomes for patients with and without coexistent adenomyosis, according to a study published November 7 in the Journal of Vascular and Interventional Radiology. Patients with both fibroids and adenomyosis faced a higher hazard of later hysterectomy than those with fibroids alone.
Why it matters
The findings suggest that short-term safety of the procedure does not differ by adenomyosis status, but patients with coexisting disease may need more durable treatment planning. The results help clinicians set expectations about the likelihood of future surgery for women considering this option.
The retrospective analysis of 13,098 commercially insured women aged 30 to 55 who underwent the procedure between 2013 and 2025 found a 41% higher hysterectomy hazard with coexistent adenomyosis (HR 1.41), with 5-year hysterectomy incidence at 20.5% versus 13.9% for fibroids alone. Because the data come from claims records, clinical factors such as symptom severity and imaging detail are not available to explain the difference.
The players
Tarub Mabud, MD
Lead researcher and physician affiliated with Columbia University Medical Center in New York, who led the MarketScan claims analysis of uterine artery embolization outcomes.
Columbia University Medical Center
Academic medical center in New York City that housed the lead researchers conducting the retrospective study.
Journal of Vascular and Interventional Radiology
Peer-reviewed medical journal published by the Society of Interventional Radiology that carried the study findings.
The details
Researchers led by Tarub Mabud, MD, of Columbia University Medical Center in New York compared fibroid-only patients with those who had both fibroids and adenomyosis. Only the hysterectomy association remained statistically significant across all sensitivity analyses, while the 21% higher hazard of any reintervention was borderline (p = 0.05). The authors advised that pre-procedural counseling should address the possibility of subsequent hysterectomy.
Timeline
Patients in the study underwent uterine artery embolization between 2013 and 2025.
The findings were published November 7 in the Journal of Vascular and Interventional Radiology.
Major adverse events were tracked for 30 days after the index procedure.
Hysterectomy incidence was measured at five years after treatment.
Health Landscape
Uterine artery embolization is a established minimally invasive alternative to hysterectomy for fibroids, and this claims-based study adds longer-term durability data drawn from the MarketScan Commercial Database. The finding that coexisting adenomyosis is linked to later hysterectomy refines how clinicians weigh this procedure against surgical options for women with overlapping conditions.
Women considering uterine artery embolization for fibroids may want to discuss with their doctor the higher chance of needing a later hysterectomy if adenomyosis is also present. Short-term complication rates were similar regardless of adenomyosis status, so the decision rests largely on longer-term treatment goals.
The takeaway
Women with both fibroids and adenomyosis should ask their clinicians about the higher likelihood of future hysterectomy before choosing embolization. Pre-procedure counseling that covers long-term outcomes is the key step highlighted by the authors.
Further reading
For broader medical context, explore more coverage in Stroke.
Source note: This article includes information reported by AuntMinnie.
Live Poll
Would you trust a minimally invasive procedure to treat fibroids instead of surgery?










